CREQF yields 2222.22% · JNJ yields 2.13%● Live data
📍 CREQF pulled ahead of the other in Year 1
Combined, CREQF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CREQF + JNJ for your $10,000?
China Rare Earth Holdings Limited, an investment holding company, engages in manufacturing and selling rare earth products and refractory products in the People's Republic of China, Japan, Europe, and internationally. It offers rare earth products for use in electronic devices, computers, electronic motors, LCDs, DVDs, magnetic materials, magnetic memory chips, fiber optics, superconductors, mobile phone batteries, precision optics, and various energy-saving environmental protection products. The company also provides refractory products, such as high temperature ceramics products for use in heat-treatment facilities for the petrochemical, steel metallurgy, non-ferrous metallurgy, glass, construction material, chemical fertilizer, and ceramics industries. In addition, it engages in the trading of rare earth products; and manufacture and sale of magnesium grains products. The company was formerly known as Yixing Xinwei Holdings Limited and changed its name to China Rare Earth Holdings Limited in May 2000. China Rare Earth Holdings Limited was founded in 1987 and is headquartered in Yixing, the People's Republic of China.
Full CREQF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.